Background-A decrease in sarcoplasmic reticulum Ca 2ϩ pump (SERCA2) activity is believed to play a role in the impairment of diastolic function of the failing heart. Because the expression ratio of phospholamban (PL) to SERCA2 may be a target to improve contractile dysfunction, a PL antisense RNA strategy was developed under the control of either a constitutive cytomegalovirus (CMV) or an inducible atrial natriuretic factor (ANF) promoter. The latter is upregulated in hypertrophied and failing heart, allowing "induction-by-disease" gene therapy. Methods and Results-Part of the PL cDNA was cloned in antisense and sense directions into adenovectors under the control of either a CMV (Ad5CMVPLas and Ad5CMVPLs, respectively) or ANF (Ad5ANFPLas and Ad5ANFPLs, respectively) promoter. Infection of cultured rat neonatal cardiomyocytes with Ad5CMVPLas reduced PL mRNA to 30Ϯ7% of baseline and PL protein to 24Ϯ3% within 48 and 72 hours, respectively. The effects were vector dose dependent. Ad5CMVPLas increased the Ca 2ϩ sensitivity of SERCA2 and reduced the time to 50% recovery of the Ca
T he heart adapts to increased workload by responding to mechanical and endocrine, paracrine, and autocrine factors that induce hypertrophy of ventricular myocytes. Although this response is initially compensatory by increasing cardiac output, sustained excessive workload ultimately leads to heart failure. 1 The ␤-adrenoceptor and sarcoplasmic reticulum (SR) Ca 2ϩ pump (SERCA2) genes are downregulated and the atrial natriuretic factor (ANF) gene is strongly upregulated in hypertrophied and failing human myocardium. [2] [3] [4] [5] The decrease in SR Ca 2ϩ pump activity is believed to be involved in the diastolic dysfunction of the failing heart. 1, 4, 5 The SR Ca 2ϩ pump in the normal heart is inhibited by the regulatory protein phospholamban (PL); this effect is relieved by ␤-adrenergic stimulation. 6 Studies on (heterozygous) PL-knockout and PL-overexpressing mice have indicated that the expression ratio of PL to SERCA2 is a potential target for improvement of diastolic function of the failing heart. 7 Cardiac overexpression of SERCA2 and PL by efficient adenovirus-mediated gene transfer indeed led to shortening and prolongation of the relaxation phase, respectively. 8, 9 These studies used viral promoters, resulting in ubiquitous and constitutive transgene expression. Cardiac troponin T and myosin heavy-and light-chain promoters have also been applied, but only the latter displayed reporter activity exclusively in ventricles. 10, 11 In this study, we used an antisense RNA strategy directed against de novo synthesis of PL under control of cytomegalovirus (CMV) or ANF promoter. The latter is strongly upregulated in hypertrophied and failing myocardium and therefore is used to evaluate the concept of "induction-bydisease" gene therapy. 3, 5 Many studies on signaling involved in hypertrophy and changes in gene expression have used the model of cultured neonatal rat cardiomyocytes stimulated by stretch or agonists such as endothelin-1 (ET-1). [12] [13] [14] Therefore, this model was used to test the effectiveness of the newly developed adenovectors on PL expression, SR Ca 2ϩ uptake activity, and Ca 2ϩ transients. 
Methods

Materials
Isolation of PL cDNA
PL cDNA was obtained by screening of a rat cDNA library (Lambda ZAP, Stratagene) with a probe derived from genomic DNA containing promoter and exon 1 of PL (unpublished). One cDNA (clone 321, 586 bp) appeared to be identical to previously published sequences, with minor differences in the 3Ј trailer, 15 and was used for construction of the adenovirus shuttle plasmids.
Development of Recombinant Adenoviral Vectors
Recombinant adenoviral vectors expressing a partial PL antisense mRNA (Ad5CMVPLas) or sense mRNA (Ad5CMVPLs), respectively, under the control of a CMV promoter were developed. 16, 17 A 230-bp EcoRI-TaqI fragment of PL cDNA containing the translation start codon (Figure 1 ) was inserted into the polylinker of pCMVI in antisense or sense orientation. The resulting CMV promoter expression plasmids were cotransfected with circularized adenoviral genome pJM17 into 293 cells. Viral plaques appeared between 10 and 20 days and were screened for recombinant virus. 16, 17 Recombinant vectors expressing a partial PL antisense RNA (Ad5ANFPLas) or sense (Ad5ANFPLs) RNA, respectively, under control of an ANF promoter were developed as follows: The ANF promoter (680-bp EcoRI-BamHI), a kind gift from K.R. Chien (University of California, San Diego), was first cloned in pCAT3 (ANF-CAT) to prove its ET-1 inducibility in rat cardiomyocytes transfected by gene gun biolistics by use of a chloramphenicol acetyltransferase (CAT) ELISA assay (Boehringer). 18 -20 The partial PL cDNA was inserted into the ANF-CAT plasmid in antisense or sense orientation, thereby eliminating the CAT reporter and introducing a chimeric intron between ANF promoter and PL cDNA. Next, EcoRI-BamHI fragments (1521 bp) containing the ANF promoter, followed by the partial PL cDNA and the SV40 poly-A signal, were cloned into the plasmid p⌬E1sp1A yielding transfer plasmids with structures similar to those used for Ad5CMVPLs and Ad5CMVPLas, but with ANF instead of CMV promoter. After cotransfection with pJM17 into 293 cells, viral plaques were screened for recombinant virus. Purified positive plaques were grown in large quantities on 293 cell cultures and purified by standard CsCl ultracentrifugation and desalting. 16 2 dishes) or in 600 L (20-cm 2 dishes) serum-free medium for 3 hours and continued for 72 hours after addition of 600 or 2600 L serum-free medium, respectively. When appropriate, after 3 hours, ET-1 (10 Ϫ8 mol/L) was added to induce hypertrophy. 13, 18, 19, 21 Analyses in addition to the plaque assays were carried out to confirm that the relative functional activities of the viruses closely matched: (1) CMV vector doses were tested at the RNA level by hybridizing Northern blots ( Figure 2 ) with SV40 probe specifically recognizing vector-derived RNA, and similar transcriptional activities (relative to GAPDH) were found; and (2) ANF vectors, because of their low expression levels, were tested instead by semiquantitative PCR of infected cells, followed by gel electrophoresis and quantification of the PCR products (not shown).
Northern Blotting
Total cardiomyocyte RNA was isolated by the guanidinium isothiocyanate method, separated on 1% denaturing formaldehyde-agarose gels, and blotted onto Hybond (Amersham). Probes were labeled by random priming with [␣-32 P]dCTP: PL; the TaqI-EcoRI fragment of the PL cDNA (excluding the part used for the constructs, Figure 1) ; GAPDH, developed by RT-PCR on rat heart RNA; and SV40, the SV40 poly A fragment of pCMVI plasmid. Hybridization and washing were carried out as described. 13 Hybridization signals were quantified by Molecular Imager (BioRad) and corrected for GAPDH. Two bands were detected with the PL probe and coquantified.
Western Blotting
Cardiomyocytes were homogenized into 10 mmol/L Tris-HCl, 0.3 mol/L sucrose, 1 mmol/L dithiothreitol, and 3 mmol/L NaN 3 by freeze-thawing. Protein (10 g) in SDS loading dye (not boiled) was separated with an SDS-PAGE 7.5% to 15% gradient gel and blotted onto PVDF (Amersham). Blots were incubated with monoclonal anti-PL (1:2500) (clone 20/2 [Affinity Bioreagents]) or anti-SERCA2 (1:1000) (clone 2A7-A1, BIOMOL Research Laboratory) as primary antibody followed by 125 I-labeled goat antimouse IgG (1:1000) as secondary antibody. After washing, blots were quantified in the molecular imager. The major band (pentameric form of PL, PL V ) was quantified.
Ca
2؉ Affinity of the SR Ca 2؉ Pump
Oxalate-dependent and thapsigargin (1 mol/L)-sensitive Ca 2ϩ uptake activity at different free Ca 2ϩ concentrations was measured in infected and noninfected cardiomyocyte homogenates. 22 Briefly, cardiomyocytes were frozen in liquid N 2 and homogenized in 100 L 0.3 mol/L sucrose, 20 mmol/L imidazole (pH 7.0), and 10 mmol/L Na 2 S 2 O 5 (to stabilize SR Ca 2ϩ pump 23 ) with a microdismembrator (Braun). Protein (20 g) was preincubated at 37°C for 2 minutes in 410 
Statistical Analysis
One-way ANOVA was performed, followed by multiple comparison by Student-Newman-Keuls test, with the statistical computer program SigmaStat. Significance was set at PϽ0.05 for Ն4 independent experiments.
Results
Cellular PL mRNA and Protein
Cardiomyocytes were infected with 2 different doses of the vectors Ad5CMVPLas and Ad5CMVPLs (MOI 5 and 10) to study their effects on PL expression. A marked and vectordose-dependent reduction in PL mRNA is apparent after 24 hours of infection with Ad5CMVPLas (88Ϯ14% and 68Ϯ19% left at MOI 5 and 10, respectively) and becomes more pronounced after 48 hours (53Ϯ1% and 30Ϯ7% left, respectively) ( Figure 2 ). Subsequently, we examined the effect of the CMV vectors on PL protein. A significant decrease in PL protein content was first visible 48 hours after infection with Ad5CMVPLas (90Ϯ11% [PϭNS], 63Ϯ3%, and 55Ϯ6% left at MOI 2.5, 5, and 10, respectively), becoming more pronounced after 72 hours (69Ϯ9%, 42Ϯ10%, and 24Ϯ3% left, respectively) ( Figure 3) . Like control cells, incubation with Ad5CMVPLs virus produced no effects, indicating specificity of the antisense effect.
Cellular SR Ca 2؉ Pump Activity and SERCA2 Protein
We measured oxalate-and ATP-dependent Ca 2ϩ uptake in homogenates of control and infected cardiomyocytes at different nonsaturating free [Ca 2ϩ ] i (pCa 5 to 7). No significant effect of Ad5CMVPLas (MOI 10) on Ca 2ϩ uptake activity was seen 48 hours after infection ( Figure 4A ), but at 72 hours, the relative Ca 2ϩ uptake activity at pCa 6.5 was significantly increased compared with control and Ad5CMVPLs-infected cells ( Figure 4B ). No effect of Ad5CMVPLas was seen at pCa 6, when Ca 2ϩ uptake activity is closer to maximum reached at pCa 5. After 72 hours, Ad5CMVPLas reduced maximal Ca 2ϩ pump activity, which cannot be explained by cell loss, because total protein content remained unchanged (legend to Figure 4) . A partial reduction of SERCA2 protein after 72 hours of Ad5CMVPLas infection (57.9Ϯ6.4% left, 
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PϽ0.05 versus uninfected or Ad5CMVPLs-infected cells) was observed, however, which may explain the decrease of maximal Ca 2ϩ uptake activity ( Figure 5 ).
Ca
2؉ Transients After Infection With Ad5CMVPLas
To determine whether depletion of PL protein by Ad5CMVPLas also alters the duration of the Ca 2ϩ transient of intact cardiomyocytes, the specific fluorescence of fura 2-loaded cells was recorded at fixed beating frequency (1 Hz). Time to 50% recovery of Ca 2ϩ transients was already lower after 48 hours in Ad5CMVPLas (MOI 5)-infected cells (245Ϯ98 ms; nϭ42, PϽ0.05 versus uninfected and Ad5CMVPLs-infected cells) compared with uninfected (593Ϯ88 ms; nϭ4) and Ad5CMVPLs-infected cells (564Ϯ38 ms; nϭ7), indicating that by decrease of PL content, the removal rate of Ca 2ϩ from myofilaments during relaxation of the cardiomyocytes is increased (see representative average Ca 2ϩ transient recordings in Figure 6 ).
Cellular PL Protein After Infection With Ad5ANFPLas
The ANF promoter fragment used was first tested for ET-1 responsiveness and displayed low activity in nonstimulated gene-gun-transfected cardiomyocytes. 18, 19 On ET-1 (10 Ϫ8 mol/L) stimulation, the promoter activity increased 2.5-fold. 18 Figure 6 depicts PL protein expression obtained 48 and 72 hours after infection with Ad5ANFPLas (MOI 10) with or without ET-1 stimulation. Earlier, we showed that in unstimulated cells, ANF mRNA is present in low but significant amounts. 13, 19 This explains the decrease in PL protein that was measured in Ad5ANFPLas-infected cells also in the absence of ET-1 ( Figure 7 , at 72 hours, 86Ϯ6% left versus noninfected cells). However, Ad5ANFPLas in the presence of ET-1 resulted in a significant further reduction of PL protein (72Ϯ7% left). Ad5ANFPLs had no effect, indicating specificity of the antisense effect.
Discussion
Infection of cardiomyocytes with Ad5CMVPLas resulted in a dramatic decrease in endogenous PL mRNA expression after 48 hours, presumably by increased degradation of the message. The vector generating partial sense mRNA and perhaps truncated PL protein clearly had no effect on endogenous PL mRNA or protein, indicating the specificity of the antisense effect. Downregulation of PL protein lags Ϸ24 hours behind that of PL mRNA, indicating that no compensatory posttranscriptional mechanisms are present.
Downregulation of SERCA2 in hypertrophied and/or failing myocardium is believed to play a role in the diastolic dysfunction. Several studies reported downregulation of PL in failing heart as well, but generally not as much as SERCA2. 4, 5 Because PL in anomalous phosphorylation states may also occur in severe heart failure, 26 antisense suppression of the endogenous PL gene may have an advantage over the enhancement of SERCA2 gene expression. Gene enhancement will not influence preexisting malfunctioning endogenous gene products, whereas antisense-based gene suppression can do so. The reduced expression of PL caused by Ad5CMVPLas results in increased Ca 2ϩ affinity of the SR Ca 2ϩ pump and in decreased time to 50% recovery of the Ca 2ϩ transients of intact cells. This is consistent with a very recent report by He et al, 27 who showed increased shortening as well as relengthening velocity in adult rabbit cardiomyocytes infected with an adenovector expressing a dominant negative mutant PL protein. However, in our present study on monolayer cultures of cardiomyocytes, we were unable to measure relative shortening of the cells during stimulation, because rhythmic displacement of cell boundaries is hard to relate to initial length of the myocytes concerned. Moreover, extrapolation of results on contractile motion of unloaded myocytes to the in vivo situation is doubtful. Ad5CMVPLas infection (72 hours) of cardiomyocytes not only increased the Ca 2ϩ affinity of SR Ca 2ϩ pump but also partially reduced its maximal activity. The latter effect is probably due to decreased SERCA2 expression ( Figure 5 ). At present, it is unclear whether this adenovector effect indicates counterregulatory systems in cardiac Ca 2ϩ homeostasis. Conversely, by suppression of endogenous PL protein, the ␤-adrenergic response becomes blunted. In failing myocardium, however, ␤-adrenoceptors are reduced and the associated regulatory components functionally altered, causing the attenuated ␤-adrenergic response. 2 Interestingly, myocytes isolated from hearts of PL-knockout mice retained the relaxant effect evoked by catecholamine. 28 Troponin I phosphorylation may increase the "off rate" for Ca 2ϩ exchange, with troponin C compensating for the effect of PL ablation on the ␤-adrenergic response.
Our development of inducible ANF promotor vectors for induction-by-disease gene therapy takes advantage of the fact that the cardiac hypertrophic phenotype in vivo and in vitro is characterized by transcriptional upregulation of distinct genes. 3, 5, 12, 13, 19, 20 Unlike the in vivo situation, a low expression of ANF is present in nonstimulated cardiomyocytes, [12] [13] [14] 19 which explains the small reduction by treatment with Ad5ANFPLas even in the absence of ET-1. In the presence of ET-1, however, a stronger reduction of PL protein was observed, consistent with the known ET-1 responsiveness of the ANF promoter. [12] [13] [14] These results are a first demonstration in cardiomyocytes of the feasibility of using a heart-specific promoter that becomes activated when the cells become hypertrophic. Another advantage is the expected return of this promoter to minimal activity when the myocytes improve in contractile function because of treatment. Knowlton et al 29 tested the same rat ANF promoter in transgenic mice with hypertrophy induced by pressure overload. In this model, the rat ANF promoter did confer cell-specific expression but not inducibility on pressure overload. Possibly, transgenic mice may compensate for the effects of the transgene during development, or species difference of rat promoter versus transgenic mice may be responsible for the lack of inducibility. 29 Hajjar et al 30 first described a method yielding high adenovector transfer rates in vivo specifically to the rat ventricles. We could confirm those findings using an adenovector expressing green fluorescent protein, thus opening a way to test the PL antisense adenovectors in vivo. 31 In conclusion, the present study suggests that vector-mediated PL antisense RNA expression may become a feasible approach to improve contractile dysfunction of the failing heart. The inducible ANF promoter offers the perspective for induction-by-disease gene therapy by selective expression of therapeutic genes in the hypertrophied and failing myocytes. 
